Status:
COMPLETED
Prediction of Drug Interactions With CYP2C9 Substrates
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Healthy Volunteers
Eligibility:
All Genders
20-50 years
Phase:
NA
Brief Summary
CYP2C9, is one of the major drug metabolism enzymes accounting for about 20% of the hepatic cytochrome P450 content and being second only to CYP3A4. The proposed study will explore different possible...
Eligibility Criteria
Inclusion
- Age range 20-50
- Absence of significant disease states
Exclusion
- Known hypersensitivity to one of the drugs used in the study
- Significant disease states
- Regular use of drugs (including birth control pills)
Key Trial Info
Start Date :
August 1 1999
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00226538
Start Date
August 1 1999
Last Update
October 29 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel